Jing Jing Wang

A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis

M. Benatar, G. Cutter, R. Barohn, 2013, Muscle & nerve.

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

M. Benatar, R. Barohn, J. Kissel, 2019, Muscle & nerve.

Correlation between myasthenia gravis−activities of daily living (MG‐ADL) and quantitative myasthenia gravis (QMG) assessments of anti−acetylcholine receptor antibody−positive refractory generalized myasthenia gravis in the phase 3 regain study

J. Vissing, J. Howard, F. O'Brien, 2018, Muscle & nerve.

QMG and MG‐ADL correlations: Study of eculizumab treatment of myasthenia gravis

J. Kissel, J. Howard, M. Freimer, 2017, Muscle & nerve.

Marked clinical and jitter improvement after eculizumab in refractory myasthenia

J. Howard, D. Sanders, L. Hobson‐Webb, 2017, Muscle & nerve.

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

M. Benatar, R. Barohn, J. Kissel, 2019, Muscle & nerve.